肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）

2021-06-11 美国泌尿外科学会 Journal of Urology

肾癌泌尿生殖系肿瘤

2021年6月，美国泌尿外科学会(AUA)发布了肾脏肿块和局限性肾癌的评估，管理和随访指南，本文为该指南的第一部分，主要内容涉及肾脏肿块和局限性肾癌的初始评估和治疗。

中文标题：

2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）

英文标题：

Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I

发布机构：

美国泌尿外科学会

发布日期：

2021-06-11

简要介绍：

2021年6月，美国泌尿外科学会(AUA)发布了肾脏肿块和局限性肾癌的评估，管理和随访指南，本文为该指南的第一部分，主要内容涉及肾脏肿块和局限性肾癌的初始评估和治疗。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=235c01c0022ea020, title=2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）, enTitle=Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline Part I, guiderFrom=Journal of Urology, authorId=0, author=, summary=2021年6月，美国泌尿外科学会(AUA)发布了肾脏肿块和局限性肾癌的评估，管理和随访指南，本文为该指南的第一部分，主要内容涉及肾脏肿块和局限性肾癌的初始评估和治疗。, cover=https://img.medsci.cn/20211129/1638150217260_1608702.jpg, journalId=0, articlesId=null, associationId=87, associationName=美国泌尿外科学会, associationIntro=AUA成立于1902年， 是全球泌尿外科领域最具影响力的学术组织之一，在全球化的背景下，联合世界各地的泌尿专家促进了学术界的最新科学研究以及临床治疗，确保世界各地的患者都能接收到最高水平的治疗。 出版包括Journal of Urology在内的多种重要刊物。, copyright=0, guiderPublishedTime=Fri Jun 11 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年6月，美国泌尿外科学会(AUA)发布了肾脏肿块和局限性肾癌的评估，管理和随访指南，本文为该指南的第一部分，主要内容涉及肾脏肿块和局限性肾癌的初始评估和治疗。</span></p>, tagList=[TagDto(tagId=330, tagName=肾癌), TagDto(tagId=117298, tagName=泌尿生殖系肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=330, guiderKeyword=肾癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2035, appHits=77, showAppHits=0, pcHits=348, showPcHits=1958, likes=0, shares=10, comments=5, approvalStatus=1, publishedTime=Mon Nov 29 10:04:25 CST 2021, publishedTimeString=2021-06-11, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Mon Nov 29 09:47:35 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 07:23:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）.pdf)])
2021 AUA指南：肾脏肿块和局限性肾癌：评估，管理和随访（第1部分）.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2159881, encodeId=c62421598813a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34bd8757253, createdName=ms2000001052964771, createdTime=Tue Sep 26 20:44:41 CST 2023, time=2023-09-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1221328, encodeId=c7e21221328f0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe086471140, createdName=ms9000001252511009, createdTime=Sat May 21 06:44:49 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077609, encodeId=12dd10e760926, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcKvRg31a63sZDpdAibIlvcmic3YEBVp1tyyp1O1ViajV2742nZfWXS8JjIJrnBjlvnY4xdW69ZH53g/132, createdBy=207c5097942, createdName=尿尿尿不到, createdTime=Tue Dec 07 07:45:20 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075308, encodeId=160c10e530846, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:53 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2023-09-26 ms2000001052964771 来自江苏省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2159881, encodeId=c62421598813a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34bd8757253, createdName=ms2000001052964771, createdTime=Tue Sep 26 20:44:41 CST 2023, time=2023-09-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1221328, encodeId=c7e21221328f0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe086471140, createdName=ms9000001252511009, createdTime=Sat May 21 06:44:49 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077609, encodeId=12dd10e760926, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcKvRg31a63sZDpdAibIlvcmic3YEBVp1tyyp1O1ViajV2742nZfWXS8JjIJrnBjlvnY4xdW69ZH53g/132, createdBy=207c5097942, createdName=尿尿尿不到, createdTime=Tue Dec 07 07:45:20 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075308, encodeId=160c10e530846, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:53 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-05-21 ms9000001252511009

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2159881, encodeId=c62421598813a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34bd8757253, createdName=ms2000001052964771, createdTime=Tue Sep 26 20:44:41 CST 2023, time=2023-09-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1221328, encodeId=c7e21221328f0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe086471140, createdName=ms9000001252511009, createdTime=Sat May 21 06:44:49 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077609, encodeId=12dd10e760926, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcKvRg31a63sZDpdAibIlvcmic3YEBVp1tyyp1O1ViajV2742nZfWXS8JjIJrnBjlvnY4xdW69ZH53g/132, createdBy=207c5097942, createdName=尿尿尿不到, createdTime=Tue Dec 07 07:45:20 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075308, encodeId=160c10e530846, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:53 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-07 尿尿尿不到

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2159881, encodeId=c62421598813a, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34bd8757253, createdName=ms2000001052964771, createdTime=Tue Sep 26 20:44:41 CST 2023, time=2023-09-26, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1221328, encodeId=c7e21221328f0, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe086471140, createdName=ms9000001252511009, createdTime=Sat May 21 06:44:49 CST 2022, time=2022-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077609, encodeId=12dd10e760926, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eqcKvRg31a63sZDpdAibIlvcmic3YEBVp1tyyp1O1ViajV2742nZfWXS8JjIJrnBjlvnY4xdW69ZH53g/132, createdBy=207c5097942, createdName=尿尿尿不到, createdTime=Tue Dec 07 07:45:20 CST 2021, time=2021-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075308, encodeId=160c10e530846, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Tue Nov 30 07:04:53 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 微探

    学习学习

    0

相关指南

抗肿瘤药物处方审核专家共识：肾癌

中国药师专家小组（统称） · 2021-06-20

高危非转移性肾癌术后辅助治疗中国专家共识（2020）

中国抗癌协会(CACA,Chinese Anti-cancer Association) 泌尿男生殖系肿瘤专业委员会 · 2021-04-03

肾癌分子靶向药物——阿昔替尼用药安全共识

中国医促会泌尿健康促进分会 · 2020-11-30

肾癌分子靶向药舒尼替尼用药安全共识

中国医促会泌尿健康促进分会 · 2020-10-20

2020年欧洲泌尿协会肾癌诊断和治疗指南概要

暂未更新 · 2020-10-20

肾癌骨转移专家共识（2020 版）

暂未更新 · 2020-07-30

拓展阅读

2008 肾癌骨转移临床诊疗专家共识（2008版）

恶性肿瘤骨转移及骨相关疾病临床诊疗专家组 · 2010-04-01

2013 AUA 肾癌患者随访指南

美国泌尿外科学会(AUA,American Urological Association) · 2013-04-01

2015中国肾癌靶向治疗药物不良反应管理专家共识

中华医学会泌尿外科学分会(CUA) · 2016-04-27

肾癌伴静脉瘤栓北京专家共识

北京市瘤栓协作小组 · 2017-12-30

肾癌诊疗规范（2018年版）

中华人民共和国国家卫生健康委员会 · 2018-12-13

肾癌靶向药物治疗安全共识

中国医促会泌尿健康促进分会 · 2019-10-30